Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure

American Journal of Physiology - Renal Physiology

Volumn 290, Issue 2, 2006, Pages

  Costello Boerrigter, Lisa C ^a   Smith, William B ^b   Boerrigter, Guido ^a   Ouyang, John ^c   Zimmer, Christopher A ^c   Orlandi, Cesare ^c   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

^b New Orleans Center for Clinical Research   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aquaretics; Congestive heart failure; V2 receptor antagonism

Indexed keywords

ARGIPRESSIN; ELECTROLYTE; FUROSEMIDE; NEUROHORMONE; PLACEBO; POTASSIUM; SODIUM; TOLVAPTAN; VASOPRESSIN V2 RECEPTOR; BENZAZEPINE DERIVATIVE; DIURETIC AGENT; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR; WATER;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIURESIS; DRUG ANTAGONISM; ELECTROLYTE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HORMONE ACTION; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE; MEAN ARTERIAL PRESSURE; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SODIUM URINE LEVEL; WATER ABSORPTION; CROSSOVER PROCEDURE; DRUG EFFECT; ELECTROLYTE BALANCE; HEMODYNAMICS; KIDNEY; METABOLISM; MICTURITION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; URINE;

BENZAZEPINES; CROSS-OVER STUDIES; DIURETICS; FEMALE; FUROSEMIDE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; KIDNEY; MALE; MIDDLE AGED; PLACEBOS; POTASSIUM; RECEPTORS, VASOPRESSIN; SODIUM; URINATION; VASOPRESSINS; WATER; WATER-ELECTROLYTE BALANCE;

EID: 33644867235     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00195.2005     Document Type: Article

References (26)

1. - cotransporter abundance: role of aldosterone. J Am Soc Nephrol 12: 1335-1341, 2001.
2. 2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 55: 633-637, 1999.
3. 1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol 284: F1115-F1119, 2003.
4. Chen HH, Redfield MM, Nordstrom LJ, Horton DP, and Burnett JC Jr. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail 10: 115-119, 2004.
5. Cooper HA, Dries DL, Davis CE, Shen YL, and Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100: 1311-1315, 1999.
6. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, and Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 42: 705-708, 2003.
7. Dries DL, Exner DV, Domanski MJ, Greenberg B, and Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35: 681-689, 2000.
8. Fuhr JJ, Kaczmarczyk KJ, and Kruttgen CD. Eine einfache colormetrische Methode zur Inulinbestimmung fuer Nieren-Clearance-Untersuchungen bei Stoffwechselgesunden und Diabetikern. Klin Wochenschr 33: 729-733, 1955.
9. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J and Orlandi C. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291: 1963-1971, 2004.
10. 2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107: 2690-2696, 2003.
11. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, and Konstam MA. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 11: 260-269, 2005.
12. Goldsmith SR. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol 95: 14-23, 2005.
13. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB and Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1: 1385-1390, 1983.
14. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, and Abraham WT. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105: 1348-1353, 2002.
15. 2 receptor antagonist. Bioorg Med Chem 7: 1743-1754, 1999.
16. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, and Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290: 2581-2587, 2003.
17. 1A receptor. Eur J Pharmacol 391: 39-48, 2000.
18. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, and Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 92: 1013-1017, 1995.
19. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, and Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003.
20. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
21. Reilly RF and Ellison DH. Mammalian distal tubule: physiology, pathophysiology, and molecular anatomy. Physiol Rev 80: 277-313, 2000.
22. Russell SD, Selaru P, Pyne DA, Ghazzi MM, Massey KD, Pressler M, Serikoff A, and Coats AJ. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am Heart J 145: 179-186, 2003.
23. Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, and Tanaka A. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 38: 198-205, 1998.
24. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104: 2417-2423, 2001.
25. Vallon V. Tubuloglomerular feedback and the control of glomerular filtration rate. News Physiol Sci 18: 169-174, 2003.
26. 2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287: 860-867, 1998.